maraviroc + fosamprenavir + ritonavir

This is a combination of three antiretroviral drugs used in the treatment of HIV-1 infection. - **Maraviroc** is a small molecule CCR5 co-receptor antagonist that blocks the entry of CCR5-tropic HIV-1 into human cells by binding to the C-C chemokine receptor type 5 (CCR5) on CD4+ cells[8]. - **Fosamprenavir** is a prodrug of amprenavir and acts as an HIV protease inhibitor; it requires activation in vivo and inhibits viral replication by preventing cleavage of viral polyproteins[1]. - **Ritonavir** is also an HIV protease inhibitor but is primarily used at low doses to boost plasma concentrations of other protease inhibitors like fosamprenavir via inhibition of cytochrome P450 3A4. This triple combination targets different stages in the HIV life cycle and is indicated for use in adults with HIV infection. Maraviroc was developed by Pfizer; fosamprenavir was developed by GlaxoSmithKline; ritonavir was developed by AbbVie. The combination has been studied for pharmacokinetic interactions and safety[3][5].

Other names

maravirocfosamprenavirritonavirUK-427857UK427857UK 427857GW433908GW-433908GW 433908ABT-538ABT538ABT 538